Is Cidara Therapeutics Inc (CDTX) Stock a Good Value Monday?

Monday, January 27, 2020 2:45 PM | InvestorsObserver Analysts

Cidara Therapeutics Inc (CDTX) is near the top in its sector according to InvestorsObserver.

CDTX gets an overall rating of 71. That means it scores higher than 71% of stocks.

Cidara Therapeutics Inc gets a 89 rank in the Healthcare sector. Healthcare is number 7 out of 11 sectors.

Click Here to get the full Stock Score Report on Cidara Therapeutics Inc (CDTX) Stock.

What do These Ratings Mean?

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as “good” for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 71 means the stock is more attractive than 71 percent of stocks.

Not only are these scores easy to understand, but it is easy to compare stocks to each other. You can find the best stock in healthcare or look for the sector that has the highest average score.

The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.)

What's Happening With Cidara Therapeutics Inc Stock Today?

Cidara Therapeutics Inc (CDTX) stock is higher by 21.19% while the S&P 500 is down -1.19% as of 2:40 PM on Monday, Jan 27. CDTX has risen $0.74 from the previous closing price of $3.47 on volume of 1,373,018 shares. Over the past year the S&P 500 is up 23.17% while CDTX has risen 49.29%. CDTX lost -$1.39 per share the over the last 12 months.

To see the top 5 stocks in Healthcare click here.

Related Companies

Upgrade to Premium and Analyze Stocks Like a Pro

50% Off All Subscriptions
InvestorsObserver Premium
InvestorsObserver Premium
InvestorsObserver Premium

InvestorsObserver Premium

$ 16.58 $ 8.29 /month
$199 $99.50 billed annually

Related Articles

Sector Update: Health Care

Sector Update: Health Care Stocks Falling as Market Rout Continues

Sector Update: Chipmakers Carrying Tech Stocks to Small Gains

Related Companies